AEON Biopharma (AEON) Proxy Filing summary

Executive summary

• Positive biosimilarity data for ABP-450 confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX, supporting the biosimilar strategy and global market positioning.

• FDA Type 2a meeting scheduled for November 19, 2025, to review analytical development plan and initial data, marking a key regulatory milestone.

• Two financing transactions—a $6 million PIPE and a Daewoong note exchange—are expected to reduce outstanding debt by over 90%, strengthen the balance sheet, and extend cash runway into Q2 2026.

• Cash and cash equivalents reported at $5.9 million as of September 30, 2025, with additional proceeds expected from recent financing.

• Forward-looking statements highlight expectations for accelerated biosimilar program development and full-label U.S. market entry.

Voting matters and shareholder proposals

• Stockholder approval is required to consummate the PIPE financing and proposed note exchange transactions.

• Proxy statement and related materials will be filed with the SEC; shareholders are urged to review these documents when available.

Board of directors and corporate governance

• Directors, executive officers, and other management may participate in proxy solicitation for stockholder approval.

• Information about directors and executive officers is available in prior proxy filings and will be updated in forthcoming materials.